PR Summary (Breast)

Note 1 Physician statement of PR (Progesterone Receptor) Summary status can be used to code this data item when no other information is available.

Note 2 The result of the PR test performed on the primary breast tissue is to be recorded in this data item.

Note 3 Results from nodal or metastatic tissue may be used ONLY when there is no evidence of in situ or invasive carcinoma in the primary tumor.

Note 4 In cases where there are invasive and in situ components in the primary tumor and PR is done on both, ignore the in situ results.

• If PR is positive on an in situ component and PR is negative on all tested invasive components in the primary tumor, code PR as negative (code 0)
• If in situ and invasive components present and PR only done on the in situ component in the primary tumor, code unknown (code 9)

Note 5 In cases where there is a single tumor with multiple biopsies and/or surgical resection with different PR results.

• Use the highest (positive versus negative)

Note 6 In cases where there are multiple tumors with different PR results, code the results from the largest tumor size (determined either clinically or pathologically) when multiple tumors are present.

• Do not use specimen size to determine the largest tumor size

Note 7 If neoadjuvant therapy is given, record the assay from tumor specimens prior to neoadjuvant therapy. If neoadjuvant therapy is given and there are no PR results from pre-treatment specimens, report the findings from post-treatment specimens.

Note 8 If the patient is PR positive and node negative, a multigene test such as Oncotype Dx may be performed, in which case another PR test will be performed. Do not record the results of that test in this field.

• Record only the results of the test which made the patient eligible to be given the multigene test